We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Adjuvant I-131 Lipiodol After Resection or Radiofrequency Ablation for Hepatocellular Carcinoma.
- Authors
Schwarz, Lilian; Bubenheim, Michael; Gardin, Isabelle; Huet, Emmanuel; Riachi, Ghassan; Clavier, Erick; Goria, Odile; Vera, Pierre; Scotté, Michel
- Abstract
Background and objectives: High rates of recurrence have been observed after curative treatment for hepatocellular carcinoma (HCC). The main aim of this study was to establish the influence of adjuvant transarterial radioembolization-based I-131 lipiodol on survival and recurrence. Methods: Between 2004 and 2010, 38 patients were treated with adjuvant I-131 lipiodol therapy, at a dosage of 2220 MBq, within 4 months after surgery. This treated cohort was compared to a control cohort consisting of 42 consecutive patients operated prior to the time the I-131 lipiodol treatment became available. Results: Recurrence-free survival in the control and in the I-131 lipiodol cohort was 12.6 and 18.7 months, respectively (HR = 1.871, p = 0.025). At 2 and 5 years, the cumulative incidence of a first recurrence or death was, respectively, 50 % and 61 % in the treated cohort versus 69 % and 74 % in the control cohort. Median overall survival was 55 and 29 months, respectively (p = 0.051). Among patients with a recurrence at 2 years, more patients had already experienced such recurrence at 1 year in the control cohort (70 % vs 33 %, p = 0.014). Conclusions: Adjuvant I-131 lipiodol improves disease-free survival in patients with HCC.
- Subjects
CATHETER ablation; LIVER cancer; CARCINOMA; CANCER; TUMORS
- Publication
World Journal of Surgery, 2016, Vol 40, Issue 8, p1941
- ISSN
0364-2313
- Publication type
Article
- DOI
10.1007/s00268-016-3502-5